Research programme: maytansinoid-antibody conjugates - Genentech
Latest Information Update: 25 Aug 2009
At a glance
- Originator Genentech
- Class Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Tubulin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Aug 2009 Preclinical development is ongoing in USA
- 09 Dec 2008 Genentech licenses the exclusive right to use ImunoGen's maytansinoid Tumor-Activated Prodrug (TAP) technology with Genentech antibodies
- 28 Apr 2005 Preclinical trials in Cancer in USA (unspecified route)